<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: A significant percentage of patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> (BE) will continue to manifest abnormal intra-oesophageal pH profiles regardless of <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi> (<z:chebi fb="4" ids="53266">PPI</z:chebi>) therapy </plain></SENT>
<SENT sid="1" pm="."><plain>AIMS: We conducted a prospective study in order to determine whether a change in <z:chebi fb="4" ids="53266">PPI</z:chebi> therapy would alter intra-oesophageal and intra-gastric acid suppression in BE patients </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS: Seventeen Helicobacter pylori-negative BE patients (16 males, 1 female; mean+/-S.D. age, 63.5+/-13.2) </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Twenty-four-hour pH monitoring was performed on <z:chebi fb="14" ids="7772">omeprazole</z:chebi> or <z:chebi fb="0" ids="6375">lansoprazole</z:chebi>, followed by repeat pH monitoring on <z:chebi fb="0" ids="8768">rabeprazole</z:chebi> at a dose titrated for symptom relief </plain></SENT>
<SENT sid="4" pm="."><plain>Patients completed validated symptom and health-related quality-of-life (HRQL) surveys while on and off therapy </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Ten (59%) of the 17 patients had abnormal baseline intra-oesophageal pH profiles </plain></SENT>
<SENT sid="6" pm="."><plain>Oesophageal pH monitoring values on <z:chebi fb="0" ids="8768">rabeprazole</z:chebi> were abnormal in five out of five (100%) of the <z:chebi fb="14" ids="7772">omeprazole</z:chebi> cohort and three out of five (60%) of the <z:chebi fb="0" ids="6375">lansoprazole</z:chebi> cohort that had abnormal pH profiles on initial testing </plain></SENT>
<SENT sid="7" pm="."><plain>Intra-gastric pH control was inadequate in BE patients on <z:hpo ids='HP_0000001'>all</z:hpo> <z:chebi fb="4" ids="53266">PPIs</z:chebi>; the mean percentage time with intra-gastric pH below 4.0 was 46% on <z:chebi fb="14" ids="7772">omeprazole</z:chebi>, 71% on <z:chebi fb="0" ids="6375">lansoprazole</z:chebi> and 51% on <z:chebi fb="0" ids="8768">rabeprazole</z:chebi> (p=0.25) </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> of the patients demonstrated the phenomenon of nocturnal acid breakthrough while undergoing <z:chebi fb="4" ids="53266">PPI</z:chebi> therapy </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Change in <z:chebi fb="4" ids="53266">PPI</z:chebi> therapy did not alter intra-oesophageal or intra-gastric control in patients with BE </plain></SENT>
</text></document>